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Background: Periodic fever syndromes (PFS) are an emerging group of autoinflammatory disorders. Clinical overlap
exists and multiple genetic analyses may be needed to assist diagnosis. We evaluated the diagnostic value of a
5-gene sequencing panel (5GP) in patients with undiagnosed PFS.
Methods: Simultaneous double strand Sanger sequencing of MEFV, MVK, TNFRSF1A, NLRP3, NLRP12 genes was
performed in 42 patients with unexplained PFS. Clinical features were correlated with genetic results.
Results: None of 42 patients analyzed displayed a causative genotype. However, single or multiple genetic variants
of uncertain significance were detected in 24 subjects. Only in 5 subjects a definite diagnosis was made by taking
into account both genetic and clinical data (2 TRAPS syndrome; 2 FMF; 1 FCAS). Statistical analysis showed that
patients carrying genetic variants in one or more of the five selected genes displayed a significantly lower response
to glucocorticoids compared with subjects who had completely negative genetic results.
Conclusions: The sequencing of multiple genes is of little help in the diagnostics of PFS and can often lead to
results of uncertain interpretation, thus the clinically driven sequencing of single genes should remain the
recommended approach. However, the presence of single or multiple genetic variants of uncertain significance,
even if not allowing any specific diagnosis, correlated with a poorer response to glucocorticoids, possibly indicating
a multifactorial subgroup of PFS with differential response to pharmacological treatment.
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Periodic fever syndromes (PFS) are an emerging group of
auto-inflammatory disorders [1]. Several well defined dis-
orders with monogenic inheritance (hereditary periodic fe-
vers HPF) have been described, including Familial
Mediterranean Fever (FMF, OMIM #134610), Hyper-IgD/
Mevalonate Kinase Deficiency syndrome (MKD, OMIM
#610377 and #260920), tumor necrosis factor alpha asso-
ciated periodic fever (TRAPS, OMIM #142680), familial
cold-induced auto-inflammatory syndrome (FCAS, OMIM
#120100) and a phenotype associated with NLRP12 muta-
tions (FCAS2, OMIM #611762) [2]. These disorders arise
from an improper control of inflammation, due to muta-
tions in inflammasome-related proteins (such as pyrin in
FMF, cryopyrin and NLRP12 in FCAS), or to defect in* Correspondence: andrea.taddio@burlo.trieste.it
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unless otherwise stated.other proteins indirectly leading to abnormal inflamma-
some activation (such as mevalonate kinase in MKD and
TNF-receptor in TRAPS) [3]. In typical cases, clinical cri-
teria driving the attention toward a single candidate gene
can assist the diagnostic process [4,5]. However, patients
may often present incomplete phenotypes or overlap signs
consistent with multiple pathological conditions. In addi-
tion, periodic fever adenitis pharyngitis aphthae syndrome
(PFAPA), which is a quite common disorder without a
definite genetic background, can also share some clinical
features with the monogenic forms of HPS [6]. In most
cases, prevalent involvement of pharynx, dramatic re-
sponse to low dose glucocortioids and complete healing
after tonsillectomy are distinctive signs confirming the
diagnosis of PFAPA. In some atypical cases, however, poor
response to steroids and/or persisting recurrence of fever
after tonsillectomy will question the diagnosis. Moreover,
patients with periodic fever displaying clinical pictures notl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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encountered in clinical practice. Accordingly, a scoring
system with a decisional algorithm has been proposed for
such ambiguous cases to facilitate the selection of patients
for specific genetic analysis [5,7]. However, even after a
careful selection, many patients remain without a genetic
diagnosis and often undergo sequence analysis for mul-
tiple PFS genes [8].
For these reasons, given also the availability of im-
proved techniques for genetic analysis with lowered
costs, we developed an assay for complete sequencing of
the five genes mostly involved in PFS (5-gene profile,
5GP),as listed in recent recommendations [9]. We ap-
plied this assay to patients with periodic fever testing
negative to a previous genetic analysis as well as to pa-
tients with atypical PFAPA syndrome (defined on the
basis of very early onset and/or poor response to gluco-
corticoids or tonsillectomy) and patients with other in-
definite forms of periodic fever.
Methods
Patients
Patients (all with European genetic background) con-
secutively referred to the IRCCS Burlo Garofolo (Trieste,
Italy) unit of pediatric rheumatology from March 2012
to April 2013 for periodic fever were enrolled in the
study. Three groups were identified based on the clinical
history: patients with a definite clinical picture of a
monogenic PFS (Group 1); patients with a clinical pic-
ture of PFAPA syndrome (Group 2); other undefined
periodic fevers (Group 3).
Group 1 included patients with specific suspect of
monogenic PFS based on the following criteria: i. Tel
Hashomer or Livneh criteria for Familial Mediterranena
Fever; ii. Recurrent fever, lymphadenopathy and diarrhea
with high levels of IgD or IgA or increased urinary
mevalonate for Mevalonate Kinase Deficiency; iii. epi-
sodes of duration longer than 1 week and presence of
myalgia or periorbital edema for TRAPS; iv. fever and
urticaria following exposure to cold for Familial cold as-
sociated periodic syndrome (FCAS) [9].
Diagnosis of PFAPA syndrome (Group 2) was based on
the presence of periodic fever and tonsillo-pharyngitis as-
sociated to cervical adenitis and/or aphthae, with onset
after 6 months, not associated with infection from group-
A beta hemolytic streptococcus.
Group 3 included all patients with unexplained peri-
odic fever presenting clinical pictures that were support-
ive neither for PFAPA nor for any specific hereditary
periodic fever syndrome.
Genetic investigation by means of the 5-genes panel
(5GP) was proposed to: i. all patients in group 1 ana-
lyzed for a single candidate gene without detection of
causative mutations (Group 1b); all patients with PFAPAwho displayed onset before 6 months or poor response
to glucocorticoids and/or to tonsillectomy (atypical-
PFAPA, Group 2b); iii. All patients in group 3. For the
purpose of this study, PFAPA was not considered atyp-
ical in cases with onset of the disease after 5 years of
age.
For each enrolled subject a standardized questionnaire
was filled, based on direct interviews and medical re-
cords (Additional file 1). The following information were
collected: episode duration and clinical features, includ-
ing symptoms, laboratory and imaging investigation re-
sults, response to treatments (steroids, colchicine).
Two patients who received alternative diagnosis during
the follow-up, were excluded from the analysis.
Genetic analysis
5GP assay. Briefly, genomic DNA was extracted from per-
ipheral blood leukocytes and all coding regions and exon-
intron boundaries regions of MEFV, MVK, TNFRSF1A,
NLRP3, NLRP12 genes were amplified in a single plate
using 59 primer pairs with a touchdown polymerase chain
reaction as reported elsewhere [10]. Bi-direction sequen-
cing has been performed using BigDye v3.1 Terminator
Cycle Sequencing kit (Life Technologies, Foster City, CA)
supplied with Betaine, (final concentration: 1 M), to ameli-
orate the amplification of GC-rich regions [11], and prod-
ucts were sequenced on ABI 3500Dx Genetic Analyzer
(Life Technologies, Foster City, CA, USA). Sequences of
both strands were imported to the SeqScape v2.7 software
(Life Technologies, Foster City, CA, USA), aligned and
compared with the published genes sequence reported in
the database National Center for Biotechnology Informa-
tion Database (NCBI). Detailed sequencing protocol is
provided on line in supplementary materials (Additional
file 1: 2a).
The interpretation of the genetic findings was per-
formed according to the recommendations of an inter-
national consensus of experts [12] for the most common
variants in MVK, MEFV, TNFRSF1A and NLRP3. For
rarer or novel variants in all genes, included NLRP12,
we referred to data from literature and to on line tools
(see Additional file 1: 2b).
Statistical analysis
For statistical purposes, genetic results were considered
“uncertain” in cases with: detection of single sequence
variants of uncertain significance; detection of multiple
sequence variants of uncertain significance as suggested
in the guidelines for the genetic diagnosis of hereditary
recurrent fevers of the European Molecular Genetics
Quality Network [12]; single heterozygous mutations for
autosomal recessive disorders, considered that in rare
cases a dominant inheritance and digenic inheritance has
been recently reported both for Familial Mediterranean
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with atypical phenotypes [13-15]. On the other hand, re-
sults were considered completely “negative” if no missense
variation or only common single-nucleotide polymor-
phisms with no proven functional consequences were de-
tected. By analyzing the clinical differences between cases
with “uncertain” compared with “negative” results we
aimed to evaluate the possible role of low penetrance or
multiple variants in the pathogenesis of multifactorial PFS.
Categorical data are presented as number and percent-
age, continuous data as median and interquartile range
(IQR). To evaluate the association between the genetic
outcome dichotomized as uncertain and negative (see
above) and possible associated variables (sex, age, dur-
ation of episodes, presence, frequency and intensity of
abdominal pain, presence and frequency of diarrhea and
thoracic pain, presence and intensity of aphthosis, pres-
ence of fever, myalgia, rash, conjunctivitis, periorbital
oedema, arthralgia or synovitis, peritonitis, pleurisy, peri-
carditis, nephritis, proteinuria, splenomegaly, response
to corticosteroids, response to colchicine, cold induced
crisis, urticaria, urethritis, the chi square test, or the FisherFigure 1 Patients who underwent the analysis of the 5 HPF- related gexact test when appropriate, were used for categorical var-
iables and the non parametric Mann Whitney test for con-
tinuous variables. The use of non parametric tests is
justified by the not normal distribution of data evaluated
both visually and with the Kolmogorov-Smirnov test. To
identify the variables strongly and independently associ-
ated with the negative outcome a multivariate logistic re-
gression analysis (forward stepwise method) was carried
out. A p value of less than 0.05 indicates a statistically sig-
nificant difference. The data were analyzed using SPSS for
Windows 21.0.
Results
Groups of enrolled patients and selection of cases for
5GP genetic analysis
A total of 93 patients were enrolled in the study. Among
these subjects, 12 were suspected of a specific mono-
genic PFS (Group 1), 58 received the diagnosis of PFAPA
syndrome (Group 2), and 23 had a clinical picture not
specific of any definite PFS (Group 3, Figure 1).
The 12 subjects from Group 1 underwent single gene
analysis. MVK was investigated in 7 subjects, MEFV inenes.
Table 1 Main clinical features in patients with uncertain
genetic results
Symptoms Uncertain genetic
results (n = 24)
Univariate
OR (95% CI)
p value
Response to
corticosteroids, n (%)#
Yes 7/19 (36.8) 0.2 (0.04-0.9) 0.03
No 10/13 (76.9)
Myalgia, n (%)
Yes 9/21 (42.9) 0.3 (0.1-1.1) 0.06
No 15/21 (71.4)
Abdominal pain and/or
diarrhea, n (%)
Yes 19/29 (65.5) 3.0 (0.8-11.8) 0.1
No 5/13 (38.5)
Arthralgia, n (%)
Yes 11/22 (50.0) 0.5 (0.2-1.9) 0.3
No 13/20 (65.0)
Tonsillitis, n (%)
Yes 14/22 (63.6) 1.8 (0.5-6.0) 0.4
No 10/20 (50.0)
Toracic pain, n (%)
Yes 2/6 (33.3) 0.3 (0.1-2.0) 0.4f
No 22/36 (61.1)
Rash, n (%)
Yes 7/14 (50.0) 0.6 (0.2-2.4) 0.5
No 17/28 (60.7)
Cold-induced crisis,
n (%)
Yes 3/4 (75.0) 2.4 (0.2-25.5) 0.6f
No 21/38 (55.3)
Response to colchicine,
n (%)*
Yes 3/5 (60.0) 1.1 (0.1-11.6) 1.0f
No 4/7 (57.1)
Splenomegaly, n (%)
Yes 3/6 (50.0) 0.7 (0.1-4.0) 1.0f
No 21/36 (58.3)
#Available for 32 subjects receiving corticosteroids.
fFisher exact test.
*Available for 12 subjects receiving colchicine.
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for the c.1129G >A (V377I) mutation in MVK and diag-
nosed as MKD. Two subjects carrying M680I (rs28940580
NM_000243.2:c.2040G > C)/V726A (rs28940579 NM_
000243.2:c.2177 T > C) and M694V(rs61752717 NM_
000243.2:c.2080A >G/R761H (rs104895097 NM_000243.2:
c.2282G >A) mutations in MEFV were diagnosed as FMF.
These three subjects, carrying high penetrance genotypes
sufficient for a definite diagnosis,were excluded from the
following study. The remaining 9 patients (2 male, 7 fe-
male, mean age 12,3 years) entered the study (Group 1b).
Among 58 subjects referred to the rheumatology unit
for periodic fever with the clinical picture of PFAPA
(Group 2), 10 have been found to display atypical fea-
tures (2 male, 8 female, mean age 6,9 years). In particu-
lar, 5 showed poor response to steroids, 3 relapsed after
tonsillectomy and 2 had disease onset before 6 months
of age (Group 2b). Moreover, 2 subjects classified as
atypical-PFAPA also had the disease onset after 5 years
of life.
Group 3 was composed by 23 subjects showing un-
defined clinical picture with periodic fever and multisyste-
mic complaints (15 male, 8 female, mean age 12,5 years).
The main clinical features are summarized in Table 1 and
Figure 2.
Genetic results
The 5GP assay was performed in 42 subjects: 9 from
Group 1b, 10 from Group 2b and 23 from Group 3
(Figure 1).
A clearly pathogenic genotype was found in none of
42 subjects. Twenty-four individuals had genetic results
of uncertain significance. In particular 11 subjects car-
ried single variants of uncertain significance in one of
the five genes analyzed, 6 subjects had variants of uncer-
tain significance in more than one gene analyzed and 7
were heterozygous for clearly pathogenic mutations as-
sociated with recessive disorders (Table 2, Figure 3).
There was no significant difference in the frequency of
genetic variants in the three groups even if heterozygous
clearly pathogenic mutations, as defined in the European
Molecular Genetics Quality Network giuidelines [12],
tended to be more common among Group 3. Tables 1
and 2 (Additional file 1: 3) show the results of the uni-
variate analysis carried out to evaluate the association
between the genetic result and clinical signs and symp-
toms. The response to corticosteroids was statistically
significantly lower in children with uncertain genetic re-
sults (36.8% vs 76.9%, OR 0.2, 95% CI 0.04-0.9, p = 0.03).
Multivariate logistic regression analysis confirmed this
result, showing that only this variable was associated to
the uncertain genetic results.
Eighteen subjects were wild type (13) or only showed
common non-pathogenic polymprphism (5).Alternative diagnosis during the follow up
After one year follow-up, different diagnosis emerged in
two cases that consequently were excluded from the
study. A 17 years old boy referred to the unit of pediatric
rheumatology for periodic fever and systemic symptoms.
Febrile episodes during follow-up were no more associ-
ated with increased acute phase reactants. The boy was
successively referred to our neuropsychiatric unit where
a Münchhausen syndrome was eventually diagnosed.
Figure 2 Descriptive differences between all the genotype subset. Legend: MU: multiple uncertain, SU: single uncertain, Hz: heterozygous,
SNP: single nucleotide polymorphism.
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the genetic analysis was successively referred to the
hematology-oncology unit of our Institute, where a diag-
nosis of Castleman disease was done. The girl entered
the study due a multisystemic picture (group 3) charac-
terized by onset at 9 years of age, recurrent and long
during fever (mean duration 15 days), frequent abdom-
inal pain, myalgia, splenomegaly and tonsillitis. The pa-
tient showed a moderate response to glucocorticoids.
Discussion
Periodic fever syndromes encompass a wide spectrum of
disorders, ranging from common multifactorial ones,
such as PFAPA syndrome, to more rare monogenic dis-
orders [16-18]. Thanks to increased awareness of these
diseases among physicians and to improved molecular
diagnostics, PFS are increasingly detected in patients
cared by various specialists for undefined inflammatory
disorders. Indeed, PFS explain a significant proportion of
recurrent fever of unknown origin in recent series [19].
Genetic testing for a number of PFS recently provided
a valuable tool to corroborate uncertain clinical diagno-
sis, resulting in increased detection and registration of
cases into international registries [20].
Since clinical overlap of symptoms with variable inten-
sity and localization is described in PFAPA and in mono-
genic PFS, decisional algorithms have been developed to
assist the selection of cases for genetic analysis [7]. Fur-
thermore, given the identification of a large number of
genetic variants in PFS genes, a consensus document
was released, with recommendation for the screening
and interpretation of genetic results for PFS [12].However, a recent retrospective study identified a large
proportion of patients categorized as PFS based on their
clinical features, in whom the genetic workup was either
negative or inconclusive [8].
We obtained similar results in our prospective study,
showing that a large proportion of cases with recurrent
fever not associated to conclusive results from genetic
analysis may be encountered in pediatric practice. Dur-
ing the period of the study, a conclusive clinical and gen-
etic diagnosis of PFS was obtained only in three subjects
who underwent genetic studies for a single candidate
gene. On the contrary, a clearly pathogenic genotype was
not found in any of the subjects enrolled in the 5GP study,
suggesting that a polygenic or multifactorial pathogenesis
may be involved in most of them. Of note, given the selec-
tion criteria of our study, the common multifactorial
PFAPA syndrome can account only for a minor propor-
tion of these cases. In fact, patients with recurrent fever
and pharyngitis were included only if displaying atypical
features such as poor response to steroids, relapse after
tonsillectomy or onset in the first 6 months of life and
represented just a quarter of our series. Indeed, most pa-
tients presented clinical pictures not supportive of any
specific PFS, while some patients had FMF, MKD or
TRAPS-like phenotype. However, a variety of uncertain or
inconclusive results were found in many subjects, ranging
from single variant of uncertain significance, multiple vari-
ants and single heterozygous mutations associated with
recessive disorders. We questioned if subjects with uncer-
tain results actually represent a distinct group compared
with subjects with completely negative genetic results as
concern clinical phenotype and response to treatments.
Table 2 Genotypes and interpretation of patients with uncertain genetic results
GENE/cDNA accession rs ID/mutation MAF (1000 g) Interpretation
1 NLRP12/NM_144687.2 rs141245482/c.910C > T H304Y < 0.01 Single mutations of uncertain significance
2 NLRP3/NM_001079821.2 rs142651552/c.2024G > A Q705K
3 NLRP12/NM_144687.2 rs34971363/c.1206C > G; F402L 0.03
4 NLRP12/NM_144687.2 rs34971363/c.1206C > G; F402L 0.03
5 NLRP12/NM_144687.2 rs34971363/c.1206C > G; F402L 0.03
6 NLRP3/NM_001079821.2 rs142651552/c.2024G > A Q705K
7 TNFRS1A/NM_001065.3 rs4149584/c.362G > A; R121Q 0.01
8 NLRP12/NM_144687.2 rs34971363/c.1206C > G; F402L 0.03
9 NLRP12/NM_144687.2 rs34971363/c.1206C > G; F402L 0.03
10 NLRP12/NM_144687.2 rs34971363F/c.1206C > G; F402L 0.03
11 TNFRS1A/NM_001065.3 rs4149584/c.362G > A; R121Q 0.01
1 MEFV/NM_000243.2 rs224222/c.602G > A; R202Q 0.17 Multiple mutations of uncertain significance
MEFV/NM_000243.2 rs224222/c.602G > A; R202Q* 0.17
2 MVK/NM_000431.2 rs7957619/c. 155G > A S52N 0.09
MVK/NM_000431.2 rs7957619/c. 155G > A S52N 0.09
3 NLRP12/NM_144687.2 rs34971363/c.1206C > G; F402L 0.03
NLRP3/NM_001079821.2 rs142651552/c.2024G > A; Q705K NA
MEFV/NM_000243.2 rs224222/c.602G > A; R202Q 0.17
MVK/NM_000431.2 rs7957619/c. 155G > A S52N 0.09
4 NLRP12/NM_144687.2 rs34971363/c.1206C > G; F402L 0.03
MEFV/NM_000243.2 rs224222/c.602G > A R202Q 0.17
5 NLRP3/NM_001079821.2 rs142651552/c.2024G > A Q705K 0.17
MEFV/NM_000243.2 rs224222/c.602G > A R202Q
6 NLRP3/NM_001079821.2 rs142651552/c.2024G > A Q705K 0.02
MEFV/NM_000243.2 rs11466023/c.1105C > T; P369S 0.02
MEFV/NM_000243.2 rs11466024/c.1223G > A; R408Q
1 MEFV/NM_000243.2 rs61732874/c.2230G > T; A744S <0.01 Heterozygous mutations associated
with autosomal recessive disorders
2 MEFV/NM_000243.2 rs3743930/c.442G > C E148Q 0.08
3 MEFV/NM_000243.2 rs11466045/c.1772T > C; I591T 0.01
4 MEFV/NM_000243.2 rs224222/c.602G > A R202Q 0.17
MEFV/NM_000243.2 rs61752717/c.2080A > G M694V 0.09
MVK/NM_000431.2 rs7957619/c. 155G > A S52N
5 MEFV/NM_000243.2 rs3743930/c.442G > C E148Q 0.08
MEFV/NM_000243.2 rs224222/c.602G > A R202Q 0.17
6 NLRP12/NM_144687.2 rs34436714 c.116G > T; G39V 0.25
MVK/NM_000431.2 rs28934897 c.1129G > A V377I
7 MEFV/NM_000243.2 rs224222/c.602G > A R202Q 0.17
MVK/NM_000431.2 rs28934897 c.1129G > A V377I
*Although hetherozygous R202Q variant in MEFV is considered a common polymorphism not to be reported, the same variant in homozygosis has been
associated to cases of Familial Mediterranean Fever in Greece [32].
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corticoids in subjects with any combination of uncertain
variants compared with negative cases, while no signifi-
cant difference was found as regards other symptoms.
A possible explanation is that a disease continuumexists between typical monogenic and multifactorial
PFS, and that some of the cases with incomplete or un-
certain genotypes may represent intermediate forms be-
tween the two ends that can display reduced response
to glucocorticoids.
Figure 3 Clinical differences according to genetic results. Legend:
MU: multiple uncertain, SU: single uncertain, Hz: heterozygous, SNP:
single nucleotide polymorphism.
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with a single heterozygous mutation in MEFV and in
rare cases a dominant pattern of inheritance has been
described [13,15,21]. Actually, the recent observation of
FMF-like PFS in subjects with double heterozygous mu-
tations in MEFV and NLRP3 raises the hypothesis that
some cases could be due to digenic or polygenic inherit-
ance [14,22]. Increasing use of genetic approaches with
simultaneous analysis of multiple PFS genes will clarify
this issue in the next future.
However, the clinical phenotype associated with het-
erozygous MEFV mutation is usually mild or atypical
and a definite diagnosis of FMF can be done only if clin-
ical criteria of the disease are satisfied [15]. In our series,
the heterozygous mutation c.442G > C in MEFV leading
to the aminoacid substitution E148Q was found in a
young man with recurrent bouts of fever and abdominal
pain that responded to colchicine and in a young girl
with atypical-PFAPA, who showed spontaneous im-
provement during follow-up. Moreover, the complex al-
lele c.1105C > T- c.1223G > A (P369S-R408Q) was found
in a girl with recurrent fever and Behcet-like complaints,
but with poor response to colchicine.
The most common variants of uncertain significance
were the c.1206C > G variation (F402L) in NLRP12, and
the c.2024G > A (Q705K) variant in NLRP3. Recent data
suggest that these variants can affect the function of the
respective proteins, however these findings are contro-
versial [23-25].
Furthermore these variants have been found with quite
high frequency in general European population, making
very difficult their correlation with clinical diagnosis
(www.1000genomes.org/). Indeed, the frequency of these
variants in our series tends to be higher than in general
population, although the difference is not statistically
significant (data not shown). However, our study was
not intended to establish if specific variants are associ-
ated or not with PFS, rather to investigate if they can
identify subgroups of PFS with distinctive features.
Some patients display multiple variants in different
genes. Even if we cannot exclude that these associationis due to chance, it is possible that they contribute to the
disease in a polygenic or multifactorial way. Digenic
pathogenesis of PSF has been recently hypothesized in
cases with double heterozygous mutations in different
genes [13-15,26].
Another possibility is that some cases are due to muta-
tions in other yet unidentified genes or to somatic mosai-
cisms not detectable with conventional genetic sequencing.
This possibility has been well documented for mutations
in NLRP3 that even when expressed in low percentages of
cells can lead to inflammatory amplification and severe
phenotypes [27-31].
Whatever the significance of the detected genotypes,
our data confirm that non-specific PFS can be encoun-
tered in pediatric practice. In most cases, the phenotype
is milder compared to most monogenic PFS, but more
serious than the common PFAPA syndrome. In fact,
during one year of follow up, spontaneous resolution oc-
curred only in 2 cases, one of them tried to simulate fe-
brile illnesses also after resolution. Indeed, we carefully
considered the possibility of simulation to explain per-
sistence of symptoms in some cases, yet only in one case
normal values of erythrocyte sedimentation rate during
crisis allowed disclosing the factious nature of the fever.
Dealing with patients affected by PFS without definite
clinical and genetic diagnosis represents a novel chal-
lenge, in particular as concern therapeutic options,
follow-up evaluation and prognosis. Some patients are
empirically treated based on the clinical and or genetic
analogy with the well defined PFS. For example, colchi-
cine was administered to 13 patients in our series, with
good response in five, regardless of the underlying geno-
type identified.
Tonsillectomy is a possible option for subjects with
atypical PFAPA syndrome with poor response to gluco-
corticoids and high frequency of crisis, however re-
sponse to surgery may be diminished in these cases, as
suggested by the presence of three patients relapsed after
tonsillectomy in our series.
Conclusions
In our experience, a target gene sequencing approach in-
cluding five PFS-associated genes showed very limited
diagnostic advantages in the diagnostics of PFS, and in
fact it often led to results of difficult interpretation.
Thus, the analysis of single genes should remain the pre-
ferred approach to the diagnostics of PFS. In addition,
we showed that a large proportion of subjects with peri-
odic fevers without a definite genetic background, based
on our current knowledge, can be commonly encoun-
tered in the clinical practice of a tertiary care depart-
ment. Longer time of follow-up and, possibly novel
genetic evaluations will clarify the clinical significance of
these group of “undifferentiated” PFS.
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